Reviewing Spero Therapeutics Inc. (SPRO)’s and Ardelyx Inc. (NASDAQ:ARDX)’s results

Both Spero Therapeutics Inc. (NASDAQ:SPRO) and Ardelyx Inc. (NASDAQ:ARDX) are each other’s competitor in the Biotechnology industry. Thus the compare of their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Spero Therapeutics Inc. 10.53M 17.66 36.09M -2.63 0.00
Ardelyx Inc. N/A 578.02 100.42M -1.68 0.00

Demonstrates Spero Therapeutics Inc. and Ardelyx Inc. earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 represents Spero Therapeutics Inc. (NASDAQ:SPRO) and Ardelyx Inc. (NASDAQ:ARDX)’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Spero Therapeutics Inc. -342.74% -48.2% -43.8%
Ardelyx Inc. 0.00% -78.4% -51.2%

Liquidity

Spero Therapeutics Inc.’s Current Ratio is 10.1 while its Quick Ratio is 10.1. On the competitive side is, Ardelyx Inc. which has a 7.4 Current Ratio and a 7.4 Quick Ratio. Spero Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Ardelyx Inc.

Analyst Recommendations

The table given features the ratings and recommendations for Spero Therapeutics Inc. and Ardelyx Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Spero Therapeutics Inc. 0 0 1 3.00
Ardelyx Inc. 0 0 0 0.00

Spero Therapeutics Inc. has a consensus target price of $28.5, and a 168.61% upside potential.

Institutional and Insider Ownership

Roughly 53.7% of Spero Therapeutics Inc. shares are owned by institutional investors while 84.6% of Ardelyx Inc. are owned by institutional investors. Insiders owned 23.71% of Spero Therapeutics Inc. shares. Competitively, insiders own roughly 1.1% of Ardelyx Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Spero Therapeutics Inc. 4.93% -2.45% 17.32% 39.09% 4.47% 93.82%
Ardelyx Inc. -3.69% -11.58% 20.38% 2.96% -42.57% 74.86%

For the past year Spero Therapeutics Inc.’s stock price has bigger growth than Ardelyx Inc.

Summary

On 7 of the 10 factors Spero Therapeutics Inc. beats Ardelyx Inc.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Ardelyx, Inc. develops and sells therapeutics for the treatment of cardio renal and gastrointestinal diseases in the United States. Its lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. The company is also developing RDX7675, which is in Phase III clinical trial for the treatment of people with hyperkalemia; and RDX8940 in Phase I clinical trial for the treatment of patients with NASH and other gastrointestinal indications. Its drug candidates in the stages of research and development include RDX013 for the treatment of patients with hyperkalemia; RDX011 for the discovery and development of second-generation NHE3 inhibitors; and RDX023 for the discovery and development of gut-biased FXR agonists for the treatment of GI and inflammatory diseases. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.